Kentaro Futatsugi

US Patent:

20110281854, Nov 17, 2011

Filed:

May 10, 2011

Appl. No.:

13/104430

Inventors:

Kentaro Futatsugi - Niantic CT, US
David W. Piotrowski - Waterford CT, US

International Classification:

A61K 31/5415
A61K 31/5383
C07D 413/04
A61K 31/5377
A61P 9/00
A61P 13/12
A61P 3/10
A61P 29/00
A61P 25/04
C07D 498/04
A61P 1/16

US Classification:

5142242, 544105, 5142305, 544131, 5142355, 544 52

Abstract:

Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.

US Patent:

20120052130, Mar 1, 2012

Filed:

Apr 12, 2010

Appl. No.:

13/318152

Inventors:

Etzer Darout - New Haven CT, US
Michael Paul DeNinno - San Diego CA, US
Kentaro Futatsugi - Niantic CT, US
Cristiano Ruch Werneck Guimaraes - Clinton CT, US
Bruce Allen Lefker - Gales Ferry CT, US
Vincent Mascitti - Groton CT, US
Kim Francis McClure - Mystic CT, US
Michael John Munchhof - Salem CT, US

International Classification:

A61K 35/56
A61K 31/506
A61K 31/497
A61K 31/55
A61K 31/536
A61K 31/566
A61K 38/22
A61K 31/4985
A61K 31/4965
A61K 38/16
A61K 31/715
A61K 38/26
A61K 31/513
A61K 31/706
A61K 31/517
A61P 3/10
A61P 3/04
A61P 3/08
A61P 3/06
A61P 9/10
A61P 9/00
A61P 19/02
A61P 19/10
A61P 13/12
A61P 7/02
A61P 25/28
A61P 25/18
A61P 25/00
A61P 1/00
C07D 239/47

US Classification:

424520, 544319, 514269, 51425407, 51421701, 5142305, 514171, 514 53, 514250, 5142521, 51421711, 514 69, 514 54, 514 72, 514249, 514274, 514 23, 5142662

Abstract:

Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPFM 19 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.

US Patent:

20120095028, Apr 19, 2012

Filed:

Mar 4, 2010

Appl. No.:

13/257384

Inventors:

Michael Paul DeNinno - Encinitas CA, US
Kentaro Futatsugi - Niantic CT, US
Bruce Allen Lefker - Gales Ferry CT, US
Vincent Mascitti - Groton CT, US
Kim Francis McClure - Mystic CT, US
Michael John Munchhof - Salem CT, US

International Classification:

A61K 31/519
A61P 13/00
A61P 3/00
A61P 3/04
A61P 3/06
A61P 3/10
A61P 9/00
A61P 19/02
A61P 19/10
A61P 9/12
A61P 13/12
A61P 15/00
A61P 9/10
A61P 15/10
A61P 17/00
A61P 25/28
A61P 25/18
A61P 1/00
C07D 471/04

US Classification:

5142641, 544280

Abstract:

Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.

US Patent:

20100285145, Nov 11, 2010

Filed:

May 6, 2010

Appl. No.:

12/774965

Inventors:

Etzer Darout - New Haven CT, US
Michael P. DeNinno - San Diego CA, US
Kentaro Futatsugi - Niantic CT, US
Cristiano Guimaraes - Clinton CT, US
Bruce A. Lefker - Gales Ferry CT, US
Vincent Mascitti - Groton CT, US
Kim F. McClure - Mystic CT, US
Michael J. Munchhof - Salem CT, US
Ralph P. Robinson - Gales Ferry CT, US

International Classification:

A61K 31/506
C07D 498/08
C07D 401/14
C07D 471/04
C07D 487/04
A61K 31/55
A61K 31/536
A61K 31/566
A61K 38/22
A61K 38/26
A61K 31/64
A61K 31/702
A61K 38/16
A61P 3/10
A61P 3/04
A61K 35/56
A61P 9/00
A61P 25/00
A61P 1/00

US Classification:

424520, 544328, 514269, 544236, 514248, 51421301, 5142305, 514171, 514 53, 514250, 51421711, 514 61, 514 69

Abstract:

Compounds of Formula (I) that modulate the activity of the G-protein-coupled receptor GPR119 and their uses in the treatment of diseases linked to the modulation of the G-protein-coupled receptor GPR119 in animals are described herein.

US Patent:

20220387402, Dec 8, 2022

Filed:

May 15, 2020

Appl. No.:

17/612672

Inventors:

- New York NY, US
Scott W. Bagley - Mystic CT, US
John M. Curto - Mystic CT, US
Matthew Dowling - Old Lyme CT, US
David James Edmonds - Riehen, CH
Dilinie Fernando - Jamaica Plain MA, US
Mark E. Flanagan - Gales Ferry CT, US
Kentaro Futatsugi - Sharon MA, US
David Andrew Griffith - Sudbury MA, US
Kim Huard - Berkeley CA, US
Gajendra Ingle - New Haven CT, US
Wenhua Jiao - Salem CT, US
Shawn M. LaCasse - Griswold CT, US
Yajing Lian - Waterford CT, US
Chris Limberakis - Pawcatuck CT, US
Allyn T. Londregan - Barrington RI, US
Alan M. Mathiowetz - Waltham MA, US
David Walter Piotrowski - Waterford CT, US
Roger B. Ruggeri - Waterford CT, US
Kristin Wiglesworth - Germantown MD, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31/438
A61K 31/496
A61K 31/4545
A61K 31/454
A61K 31/5377
A61K 31/506
A61K 31/46
A61K 45/06
A61K 38/26
A61K 38/28
A61K 38/17
A61P 1/16

Abstract:

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.

US Patent:

20230045419, Feb 9, 2023

Filed:

Dec 7, 2020

Appl. No.:

17/782478

Inventors:

- New York NY, US
Scott W. Bagley - Mystic CT, US
Wesley Dewitt Clark - Gales Ferry CT, US
John M. Curto - Mystic CT, US
David James Edmonds - Riehen, CH
Mark E. Flanagan - Gales Ferry CT, US
Kentaro Futatsugi - Sharon MA, US
David Andrew Griffith - Sudbury MA, US
Kim Huard - Berkeley CA, US
Yajing Lian - Waterford CT, US
Chris Limberakis - Pawcatuck CT, US
Allyn T. Londregan - Barrington RI, US
Alan M. Mathiowetz - Waltham MA, US
David Walter Piotrowski - Waterford CT, US
Roger B. Ruggeri - Waterford CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 405/14

Abstract:

The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.

US Patent:

20210332034, Oct 28, 2021

Filed:

Jun 13, 2019

Appl. No.:

17/251929

Inventors:

- New York NY, US
Scott W. Bagley - Mystic CT, US
Edward L. Conn - Griswold CT, US
John M. Curto - Mystic CT, US
David J. Edmonds - Basel, CH
Mark E. Flanagan - Gales Ferry CT, US
Kentaro Futatsugi - Sharon MA, US
David A. Griffith - Sudbury MA, US
Kim Huard - Berkeley CA, US
Chris Limberakis - Pawcatuck CT, US
Alan M. Mathiowetz - Waltham MA, US
David W. Piotrowski - Waterford CT, US
Roger B. Ruggeri - Waterford CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 405/14
C07D 471/04
C07D 401/14
C07D 413/14
C07D 403/14

Abstract:

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

US Patent:

20210309644, Oct 7, 2021

Filed:

Mar 23, 2021

Appl. No.:

17/209780

Inventors:

- New York NY, US
Dilinie Fernando - Jamacia Plain MA, US
Kentaro Futatsugi - Quincy MA, US
Kim Huard - Berkeley CA, US
Thomas Victor Magee - Winchester MA, US
Brian Raymer - Holliston MA, US
Andre Shavnya - East Lyme CT, US
Aaron Smith - North Providence RI, US
Benjamin Thuma - Old Lyme CT, US
Andy Tsai - Mystic CT, US
Meihua Tu - Acton MA, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 403/14
A61K 31/403
C07D 401/04
C07D 401/14
C07D 403/04

Abstract:

Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.